

F. No. BIO/CT/18/000046
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

To,

M/s Intas Pharmaceuticals Ltd.,
Corporate House, Near Sola Bridge
S.G. Highway, Thaltej, Ahmedabad – 380054, Gujarat

Subject: Permission for conducting a Phase 3 clinical trial titled "Efficacy and safety of Intas Denosumab (120 mg/1.7 mL) in comparison with Xgeva (Amgen) in patients with solid tumours with bone metastases" as per protocol no. 0182-18, version 1.1 dated 05-May-2018

Reference :- Your Application No. BIO/Form44/FF/2018/8555 dated 18-Jul-2018 on the subject mentioned above.

Sir,

This Directorate has no objection to your conducting subject mentioned study under the provisions of Drugs and Cosmetics Rules 122-DA and 122-DAC, under the supervision of the investigators mentioned below as per protocol no. 0182-18, version 1.1, dated 05-May-2018 submitted to this Directorate.

Name of Investigator	Clinical Trial Site address	Name and Address of the Ethics Committee
Dr. Davinder Paul	Dayanand Medical College and Hospital Tagore Nagar, Civil Lines, Ludhiana-141001, Punjab, India	Drugs Trial at Basement Hero DMC Heart Institue Opp. Library Dayanand Medical College and Hospital Tagore Nagar, Civil Lines, Ludhiana-141001, Punjab, India <u>EC Reg. No.:</u> <u>ECR/101/Inst/PB/2013/RR-16</u>
Dr. Ghanashya m Biswas	Sparsh Hospitala and Critical Care Private Limited Plot No.-A-407, Saheed Nagar, Bhubhneswar-751007, Khordha, Odisha, India	Sparsh Hospital and Critical Care P Ltd Plot No. A/407, Sahid Nagar, Bhubaneswar-751007, Odisha, India <u>EC Reg. No.:</u> <u>ECR/68/Inst/OR/2013/RR-16</u>
Dr. Kaushal Patel	Nirmal Hospital Pvt. Ltd Ring Road, Surat-395002, Gujarat, India	Nirmal Hospital Private Ethics Committee, Ring Road, Surat 395002 <u>EC Reg. No. :</u> <u>ECR/390/Inst/GJ/2013/RR-16</u>
Dr. Ankit Patel	Unique Hospital Multispecialty and research Institute, Opp. Kiran, Motors, Nr. Canal, Civil Hospital Char rasta-Sosyo circle Lane, Surat-395002, Gujarat, India	Unique Hospital Multispecialty and Research Institute, Opp. Kiran Motor, Nr. Canal Civil Hospital Char Rasta-Sosyo Circle lane, Surat 395002, Gujarat India <u>EC Reg. No.:</u> <u>ECR/595/Inst/GJ/2014/RR-17</u>
Dr. Amit Agarwal	B.L.K. Super Speciality Hospital Pusa Road, New Delhi, 110005, India	Dr. B. L Kapur Memorial Hospital Ethics Committee, Academic Affairs Research and Continuing Education AARCE, Dr. B. L Kapur Memorial Hospital Pusa Road, New Delhi-110005 <u>EC Reg. No.:</u> <u>ECR/3/BLK/Inst/ND/2013/RR-16</u>

Dr. P K Chaithanya	MNJ Institute of oncology and Regional Cancer MNJ Institute of oncology and Regional Cancer Red Hills, Hyderabad-500004, Telangana	MNJ Institute of Oncology and Regional Cancer Centre Red Hills, Hyderabad, Telangana <u>EC Reg. No.:</u> <u>ECR/227/Inst/AP/2013/RR-16</u>
Dr. Mangesh P Kamath	Mazumdar Shaw Medical Centre 258-A, Bommasandra Industrial Area, Anekal Taluk, Bangalore-560099, Karnataka	Narayan Health Medical Ethics Committee, 258/A Bammiasandra Industrial Area, Anekal Taluk, Bangalore, Karnataka – 560099, <u>EC Reg. No.:</u> <u>ECR/390/Inst/KA/2013/RR-16</u>
Dr. Sadashivudu Gundeti	Nizams Institute of Medical Sciences Pamjagutta, Hyderabad, Telangana, India-500082	Nizam's Institute of medical Sciences, Punjagutta, Hyderabad-500082, Telangana, India <u>EC Reg. No.:</u> <u>ECR/303/Inst/AP/2013/RR-16</u>
Dr. Rajeev L K	Sri Venkateshwar Hospitals #86 Hosur Main Road, Madiwala, Bangalore-560068, Karnataka	Sri Venkateshwar Hospital Ethics Committee, #86 Hosur Main Road, Madiwala, Bangalore-560068, Karnataka <u>EC Reg. No.:</u> <u>ECR/298/Inst/KA/2013/RR-16</u>

Licensing Authority as defined in clause (b) of Rule 21, issue permission for conduct of clinical trial, subject to the following conditions further, namely:-

(a) Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y annexed to these rules, Good Clinical Practice Guidelines for conduct of clinical trials in India and other applicable regulations.

(b) Approval of the Ethics Committee shall be obtained before initiation of the study.

(c) Clinical trial shall be registered at Clinical Trials Registry of India before enrolling the first patient for the study.

(d) Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.

(e) Any report of serious adverse event occurring during clinical trial to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.

(f) In case of an injury or death during the clinical trial to the subject of the clinical trial the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with Rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.

(g) The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trials in India and other applicable regulations.

(h) The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites and the investigator shall allow officers authorized by the Central Drug Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or

without prior notice, any premises of sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs etc. related to clinical trials and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.

(i) Submit complete report of clinical trials as per the approved protocol from the individual investigator duly signed by him along with his observations/remarks on the drug indicating the date of commencement and conclusion of the clinical trial at each center (in case the study is multicentric).

(j) Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics Committees.

(k) The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.

(l) An audio-video recording of the informed consent process in case of vulnerable subjects in clinical trials of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record. Provided that in case of clinical trial of anti-HIV and anti Leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record.

(m) It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

(n) The bulk drug to be used in the manufacturing of finished formulation intended to be used in the clinical trial and clinical trial batches of finished formulation shall be manufactured under GMP conditions using validated procedure and shall have ongoing stability program.

(o) If the clinical trial batches are different from that of the primary batches for which data have been submitted, stability report for clinical trial batches are to be submitted as per Appendix IX of Schedule Y of Drugs and Cosmetic Rules for Drug substance and formulation along with Clinical study report.

It is informed that all the amendments to Rule 122DAA, inclusion of Rule 122DAB, compensation matters etc. that are appended to the Drugs & Cosmetics Act & Rule, vide GSR 53 (E) dated 30.01.2013 and in Part X-A, after Rule 122DAB, Rule 122 DAC vide GSR 63 (E) dated 01.02.2013 are mandatory and binding.

Yours faithfully,

**S ESWARA
REDDY**

Digitally signed by S ESWARA REDDY
DN: c=IN, o=CENTRAL DRUGS
STANDARD CONTROL ORGANIZATION.,
2.5.4.20=cec9e6dd3ecf4caa36d3ae9e43
2d59a6f4c3a02cb467e76d5edc3a731
ee144, ou=DGHSCID - 6432120,
postalCode=110002, st=Delhi, cn=S
ESWARA REDDY
Date: 2018.12.20 16:34:46 +05'30'

(Dr. S. Eswara Reddy)
Drugs Controller General (India)
Licensing Authority